(Q34482014)

2 August 2017

1 reference

title

Emerging treatments for irritable bowel syndrome (English)

1 reference

2 August 2017

irritable bowel syndrome

1 reference

Joseph Ahn

1

1 reference

PubMed ID

11772329

2 August 2017

Eli D Ehrenpreis

series ordinal

2

1 reference

PubMed ID

11772329

2 August 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

1 reference

2 August 2017

3

1 reference

2 August 2017

1

1 reference

2 August 2017

9-21

1 reference

Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

The control of pain in peripheral tissue by opioids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

The irritable bowel syndrome: a paroxysmal motor disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Review article: clinical pharmacology models of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Review article: an integrated approach to the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Management of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Treatment of irritable bowel syndrome: a review of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Ischemic colitis during treatment with alosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

SB-207266: 5-HT4 receptor antagonism in human isolated gut and prevention of 5-HT-evoked sensitization of peristalsis and increased defaecation in animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Increased defecation during stress or after 5-hydroxytryptophan: selective inhibition by the 5-HT(4) receptor antagonist, SB-207266.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

5-HT4 receptor antagonism potentiates inhibition of intestinal allodynia by 5-HT3 receptor antagonism in conscious rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Pharmacological characterization of 5-HT4 receptors mediating relaxation of canine isolated rectum circular smooth muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Intestinal macrophages display reduced permissiveness to human immunodeficiency virus 1 and decreased surface CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex inrat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Fedotozine blocks hypersensitive visceral pain in conscious rats: action at peripheral kappa-opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

New drugs in the management of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

Bowel function and transit rate during the menstrual cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.1.9

21 January 2018

Identifiers

DOI

10.1517/14656566.3.1.9

1 reference

2 August 2017

1 reference

PubMed ID

11772329